Vitiligo: What's Actually Happening in Your Skin

22 June

Written By Joey .

Vitiligo is one of the most visible and psychologically impactful skin conditions in clinical practice — and one of the most mechanistically complex. Affecting approximately 0.5–2% of the global population regardless of sex, ethnicity, or skin type, it is characterised by progressive, sharply demarcated depigmented macules caused by the selective destruction of melanocytes.¹ For decades, it was treated empirically — topical steroids, phototherapy, camouflage. The last decade has transformed our understanding of vitiligo at a molecular level, uncovering a precise autoimmune cascade that is now yielding genuinely targeted therapies. Simultaneously, functional investigation of nutritional status, oxidative burden, and immune terrain has opened a complementary pathway that conventional dermatology has been slow to integrate.

This post covers the complete clinical picture: what vitiligo is, the biology of melanocyte destruction, the IFN-γ–JAK–STAT pathway, risk factors and triggers, nutritional deficiencies documented in meta-analyses, the evidence base for conventional and emerging treatments including ruxolitinib, and the functional medicine lens through which the internal terrain driving autoimmune activity can be assessed and addressed.

◆ Quick Answer

What causes vitiligo? Vitiligo is an autoimmune skin condition driven by oxidative stress–triggered melanocyte damage, followed by innate immune activation and CD8+ cytotoxic T-cell–mediated melanocyte destruction. The IFN-γ/CXCL9/CXCL10/CXCR3 axis is the dominant immunological pathway — and the primary target of the JAK inhibitor class of treatments now approved for vitiligo. Genetic predisposition, oxidative stress, nutrient deficiencies (particularly vitamin D, vitamin E, and zinc), and trigger factors including physical trauma (Koebner phenomenon), emotional stress, and chemical exposures all contribute to onset and progression.^2,3,4

What Is Vitiligo? Classification and Clinical Presentation

Vitiligo presents as well-demarcated, milk-white macules and patches — the depigmentation is characteristically complete rather than partial, distinguishing it from other hypopigmentation disorders. The condition is classified primarily into two subtypes with distinct clinical behaviour, prognosis, and treatment response:

85–90% of cases

Non-Segmental Vitiligo (NSV)

Bilateral, often symmetric distribution across the body. Associated with autoimmune conditions (thyroid disease, type 1 diabetes, alopecia areata, rheumatoid arthritis). Progressive and unpredictable course. Responds to systemic immunomodulation and phototherapy. The dominant form in adults.^1,5

10–15% of cases

Segmental Vitiligo (SV)

Unilateral, dermatomal distribution. Earlier onset, rapid initial progression that typically stabilises within 1–2 years. Lower autoimmune association. Responds poorly to systemic therapy. Surgery (melanocyte grafting) is the primary option after disease stability.^1,5

Acral / acrofacial

Acrofacial Vitiligo

Confined to the face, distal extremities, and mucosal surfaces. Often the most resistant to treatment due to lower density of follicular melanocyte reservoirs — the source from which repigmentation occurs with phototherapy.⁵

Rare, severe

Universal Vitiligo

Near-complete or complete depigmentation of the body surface. Associated with strong autoimmune history. Treatment options are limited; cosmetic camouflage and sun protection are primary management goals.¹

0.5–2% Global prevalence of vitiligo — affecting an estimated 65–95 million people worldwide across all ethnicities, skin types, and sexes equally. Up to 20% of patients have a first-degree relative with the condition.¹

The Biology of Vitiligo: How Melanocytes Are Destroyed

Understanding the mechanism of melanocyte destruction in vitiligo requires understanding the cell itself. Melanocytes are dendritic cells residing in the basal layer of the epidermis, producing and transferring melanin pigment (via melanosomes) to surrounding keratinocytes. They are uniquely vulnerable to oxidative stress due to the inherently pro-oxidant nature of melanin synthesis — the melanogenesis pathway generates reactive oxygen species (ROS) as a byproduct, making melanocytes dependent on robust antioxidant defences that are demonstrably impaired in vitiligo.⁶

Stage 1 — Oxidative Stress and Melanocyte Vulnerability

The initiating event in vitiligo pathogenesis is oxidative stress — an imbalance between ROS production and antioxidant capacity in melanocytes. Evidence for this is extensive: vitiligo patients show elevated markers of oxidative damage (malondialdehyde, 8-OHdG), reduced total antioxidant capacity (TAC), and impaired activity of antioxidant enzymes including catalase, superoxide dismutase, and glutathione peroxidase.^6,7 The accumulation of hydrogen peroxide in the epidermis — due to reduced catalase — is a particularly well-characterised finding, directly inhibiting both melanin synthesis and melanocyte survival.

Triggers that initiate or amplify this oxidative burden include: UV radiation, chemical exposure (particularly phenolic compounds used in some occupational settings), physical trauma to skin (Koebner phenomenon), psychological stress (via catecholamine-generated ROS), and certain nutritional deficiencies that impair antioxidant enzyme function — particularly zinc and vitamin E.^6,7

Stage 2 — Innate Immune Activation: DAMPs and the Danger Signal

Oxidatively stressed melanocytes release damage-associated molecular patterns (DAMPs) — particularly heat shock protein 70 (HSP70) — which act as danger signals activating innate immune cells. Dendritic cells exposed to HSP70 produce interferon-alpha (IFN-α), initiating the first wave of immune activation. Keratinocytes under oxidative stress simultaneously release IL-15, CXCL9, and CXCL10 — chemokines that drive lymphocyte recruitment.^2,8

Stage 3 — The IFN-γ / JAK-STAT Axis: The Central Autoimmune Cascade

The most critical and now most therapeutically targeted pathway in vitiligo is the IFN-γ/CXCL9/CXCL10/CXCR3 axis — the molecular mechanism through which autoimmune melanocyte destruction is orchestrated and sustained.

The IFN-γ → JAK-STAT → Melanocyte Destruction Cascade

IFN-γ release: Activated autoreactive CD8+ T cells and NK cells release interferon-gamma (IFN-γ) — the master cytokine of vitiligo pathogenesis.^2,3
JAK1/JAK2 activation: IFN-γ binds its receptor (IFNγR) on keratinocytes and melanocytes, activating Janus kinases JAK1 and JAK2, which phosphorylate STAT1.^3,8
CXCL9/CXCL10 upregulation: Activated STAT1 drives transcription of CXCL9 and CXCL10 — chemokines that recruit more CXCR3-expressing CD8+ T cells to the skin, amplifying the immune cascade in a positive feedback loop.^2,3
CD8+ T-cell–mediated killing: Recruited cytotoxic CD8+ T lymphocytes (CTLs) directly kill melanocytes via perforin/granzyme cytotoxicity and the Fas/FasL apoptosis pathway, executing the depigmentation that defines vitiligo clinically.^2,8
Resident memory T cells: After the initial attack, CD8+ tissue-resident memory T cells (Trm) persist in the skin — providing immunological memory that drives disease relapse after treatment cessation, particularly with conventional therapies that do not eliminate Trm cells.³

This cascade is why JAK inhibitors — which block JAK1/JAK2 and interrupt IFN-γ signalling — have produced the most significant therapeutic advances in vitiligo in decades. It also explains why the condition tends to relapse after stopping treatment: the upstream trigger (resident memory T cells) is not eliminated by most current therapies.

Risk Factors and Triggers

Vitiligo arises from the interaction of genetic susceptibility and environmental or physiological triggers. Neither alone is sufficient — the condition requires both a predisposed immune terrain and an activating event.

Genetic Susceptibility

Vitiligo has a strong genetic component. Up to 20% of patients have a first-degree relative with the condition. Genome-wide association studies (GWAS) have identified over 50 susceptibility loci, including genes involved in melanocyte biology (TYR, OCA2, TYRP1), immune regulation (HLA class I/II, PTPN22, FOXP1, RERE), and antioxidant defence. The genetic architecture explains the high co-occurrence with other autoimmune conditions — thyroid disease (Hashimoto's and Graves') is the most common association, found in up to 20–30% of vitiligo patients.^1,5

The Koebner Phenomenon

Physical trauma to skin — friction, cuts, burns, surgical incisions, even tight clothing — can trigger new vitiligo lesions at the site of injury. This Koebner phenomenon affects approximately 25–60% of vitiligo patients and reflects the role of local inflammatory signalling in activating the autoimmune cascade at sites of tissue damage.⁵

Chemical Triggers

Occupational and cosmetic exposure to phenolic compounds — particularly monobenzone (used in depigmentation creams), para-tertiary butylphenol (PTBP, found in some adhesives and rubber products), and catechol derivatives — can directly damage melanocytes and trigger autoimmune vitiligo in genetically susceptible individuals. This is a clinically underrecognised history point in new vitiligo presentations.^5,6

Psychological Stress

Psychological stress is among the most commonly reported triggers for both vitiligo onset and flare. Stress activates the sympathetic nervous system, elevating catecholamines that generate ROS in melanocytes, and modulates immune regulatory pathways — reducing regulatory T-cell (Treg) activity that would otherwise suppress autoreactive CD8+ T cells.⁵

Nutritional Deficiencies in Vitiligo: What the Meta-Analyses Show

The relationship between nutritional status and vitiligo is increasingly well-characterised. The 2024 meta-analysis by Iraji et al. — analysing 47 observational studies — provides the most comprehensive and current synthesis of serum micronutrient levels in vitiligo patients versus healthy controls.⁴

Vitamin D Significantly Low

Consistently reduced in vitiligo patients across multiple meta-analyses. VDR signalling modulates melanocyte differentiation and immune regulation. Vitamin D deficiency impairs Treg function — removing a key brake on autoreactive T cells.^4,9

Vitamin E Significantly Low

A fat-soluble antioxidant critical for membrane lipid protection against ROS. Reduced levels in vitiligo correlate with the oxidative stress model of melanocyte vulnerability. Supplementation studies show modest but consistent antioxidant benefit.^4,7

Zinc Significantly Low

Higher serum zinc is associated with reduced vitiligo risk (OR 0.29, p<0.001). Zinc is a cofactor for superoxide dismutase and catalase — the primary antioxidant enzymes impaired in vitiligo. Zinc also supports T-regulatory cell function and melanocyte survival.^4,10

Selenium Elevated — Caution

Counterintuitively, elevated selenium is associated with increased vitiligo risk (OR 4.31, p<0.001). Selenium excess may have a depigmenting effect. Selenium supplementation should not be assumed beneficial in vitiligo and requires careful individual assessment.^4,10

Vitamin B12 No Significant Difference

Despite historical association, the 2024 meta-analysis (47 studies) found no statistically significant difference in B12 levels between vitiligo patients and controls. Earlier positive findings may reflect smaller study bias. B12 deficiency remains relevant in autoimmune context but is not a specific vitiligo marker.⁴

Copper Conflicting Data

Results across meta-analyses are conflicting — some show decreased copper, others no difference. Copper is a cofactor for tyrosinase (the melanin-synthesising enzyme) and for superoxide dismutase. Functional copper insufficiency — even at "normal" serum levels — may be relevant in the oxidative stress model.¹⁰

Clinical note — the selenium paradox: Many patients with autoimmune skin conditions are advised to take selenium as an antioxidant. In vitiligo specifically, the evidence suggests elevated selenium may worsen the condition — with an odds ratio of 4.31 for vitiligo risk in high-selenium individuals. This is a case where population-level antioxidant recommendations require individual reassessment. Selenium supplementation is not recommended in vitiligo without a confirmed deficiency demonstrated on testing.^4,10

📄 Iraji et al., JEADV Clinical Practice (2024) — 47-Study Meta-Analysis

The most current and comprehensive meta-analysis of nutritional markers in vitiligo analysed 47 observational studies examining serum levels of vitamin D, E, B12, folic acid, selenium, copper, zinc, iron, vitamin A, and vitamin C. Key confirmed findings: significantly lower vitamin D, vitamin E, and zinc in vitiligo patients versus controls. Significantly higher selenium and folic acid. No significant difference for B12 or copper. The authors note these findings are relevant for guiding supplementation decisions — specifically, that selenium supplementation may be contraindicated in vitiligo, while vitamin D, E, and zinc represent evidence-based supplementation targets.⁴

Functional Medicine Perspective: The Internal Terrain

The functional medicine approach to vitiligo does not replace the conventional treatment pathway — it runs parallel to it, addressing the systemic drivers that create the conditions for autoimmune melanocyte destruction. These include oxidative burden, immune dysregulation, nutritional insufficiency, gut health, and inflammatory load.

Oxidative Stress Assessment and Reduction

Oxidative stress is the initiating event in vitiligo pathogenesis — not a consequence of it. Assessing and reducing the total oxidative burden is therefore a foundational clinical target. Functional markers relevant to this include: total antioxidant capacity (TAC), malondialdehyde (MDA) as a lipid peroxidation marker, glutathione (reduced and oxidised), 8-OHdG as a DNA oxidation marker, and catalase activity. Dietary antioxidant optimisation — emphasising polyphenol-rich foods, high-vitamin-E foods, and adequate dietary zinc — supports the enzymatic antioxidant defences that are structurally impaired in vitiligo melanocytes.^6,7

Vitamin D Optimisation

Given the consistent finding of vitamin D deficiency in vitiligo and its role in immune regulation — specifically in supporting Treg function that suppresses autoreactive T cells — optimising 25(OH)D to a functional target of 100–150 nmol/L is a rational clinical intervention. Vitamin D also directly modulates melanocyte differentiation and function. NB-UVB phototherapy, the most evidence-supported phototherapy for vitiligo, simultaneously drives repigmentation and raises vitamin D levels — addressing two deficits simultaneously.⁹

Gut-Immune Connection

The gut microbiome is an emerging area of vitiligo research. Dysbiosis — particularly reduction in butyrate-producing bacteria — reduces Treg cell numbers and activity, lowering the immunological threshold for autoreactive T-cell activation. The same intestinal permeability mechanisms that drive food-reactive skin conditions also generate the chronic systemic inflammatory load that predisposes to autoimmune flares. While the gut-vitiligo axis is less characterised than gut-eczema or gut-psoriasis, the mechanistic plausibility and the clinical pattern of vitiligo co-occurring with other autoimmune and inflammatory conditions is consistent with gut immune dysregulation as a terrain factor.

Thyroid and Autoimmune Co-Assessment

Given the 20–30% co-occurrence of vitiligo with autoimmune thyroid disease (Hashimoto's thyroiditis, Graves' disease), functional endocrine assessment is clinically warranted in all vitiligo patients — including TSH, free T3, free T4, and thyroid antibodies (anti-TPO, anti-TG). Undiagnosed and undertreated Hashimoto's thyroiditis represents an ongoing autoimmune inflammatory driver that can sustain vitiligo activity. Similarly, screening for other autoimmune conditions (ANA panel, coeliac serology, fasting glucose/HbA1c) provides a complete autoimmune terrain picture.⁵

✦ Functional Skin Assessment — Vitiligo

Our vitiligo assessment includes functional nutritional panel (vitamin D, E, zinc, copper), oxidative stress markers, thyroid antibody screening, gut permeability assessment, and autoimmune co-condition evaluation — providing the complete internal picture alongside clinical treatment planning.

Evidence-Based Treatments: Past, Present, and Emerging

Conventional First-Line: Topical Corticosteroids and Calcineurin Inhibitors

Topical corticosteroids remain first-line for localised vitiligo — particularly in children and patients with early or limited disease. They suppress local inflammation and have been shown to produce repigmentation in responsive patients, particularly on the face and trunk. Topical calcineurin inhibitors (tacrolimus 0.1%, pimecrolimus 1%) are preferred in sensitive areas (face, flexures, around eyes) where long-term steroid use carries atrophy risk, and have demonstrated comparable repigmentation rates to mild-to-moderate topical steroids in RCTs.¹¹

NB-UVB Phototherapy: The Gold Standard for Extensive Disease

Narrowband UVB (311–313 nm) phototherapy is the most evidence-supported treatment for extensive non-segmental vitiligo. Its mechanism in vitiligo is distinct from its mechanism in psoriasis: NB-UVB stimulates melanocyte migration, proliferation, and melanogenesis from follicular reservoirs — the melanocyte stem cells residing in the hair follicle outer root sheath that are spared from the autoimmune attack. The 2025 Global Vitiligo Guidelines recommend NB-UVB for patients with insufficient response to topical therapy or with extensive/rapidly progressive disease. Persistent repigmentation was documented in 80% of patients one year after treatment in non-segmental vitiligo.^5,12

JAK Inhibitors: The Paradigm Shift

📄 Ruxolitinib Cream 1.5% — First FDA and EMA Approved Treatment for Vitiligo (2022/2023)

Ruxolitinib cream 1.5% (Opzelura, Incyte) is now the first FDA-approved and EMA-approved topical treatment specifically for non-segmental vitiligo — representing the first regulatory approval of any treatment for vitiligo. It is a selective JAK1/JAK2 inhibitor that directly interrupts the IFN-γ/JAK-STAT signalling pathway driving melanocyte destruction. In the pivotal Phase 3 TRuE-V1 and TRuE-V2 trials, 30% of patients achieved 75% improvement in Facial Vitiligo Area Scoring Index (F-VASI75) at 24 weeks — compared to approximately 8% with vehicle. Response continues to improve beyond 24 weeks with ongoing use.^3,11,12

📄 JAK Inhibitor + NB-UVB Combination — Systematic Review and Meta-Analysis (PMC12777791, 2025)

A 2025 systematic review and meta-analysis confirmed synergistic efficacy when combining JAK inhibitors with NB-UVB phototherapy in non-segmental vitiligo. The mechanism is complementary: JAK inhibition suppresses the active autoimmune attack on melanocytes, while NB-UVB simultaneously stimulates melanocyte migration from follicular reservoirs into the depigmented areas. Baricitinib (2–4 mg/day) accelerated repigmentation in progressive NSV, while tofacitinib (5 mg twice daily) enhanced responses in refractory disease. The combination produced faster and more complete repigmentation than either modality alone.³

Treatment	Mechanism	Evidence Level	Best For	Limitations
Topical corticosteroids	Broad immunosuppression	RCT evidence — moderate	Localised, early disease	Skin atrophy with long-term use; not face
Tacrolimus 0.1%	Calcineurin inhibition — T-cell suppression	RCT evidence — moderate	Face, flexures, children	Burning, stinging; inferior to steroids for trunk
NB-UVB	Melanocyte migration from follicular reservoir + immunosuppression	High — guidelines first-line	Extensive NSV; face responds best	Time commitment; acral areas respond poorly
Ruxolitinib cream 1.5%	JAK1/2 inhibition — IFN-γ pathway blockade	High — FDA/EMA approved	NSV; best facial response	Cost; relapse on cessation; Trm cells persist
Oral JAK inhibitors	Systemic JAK1/2 inhibition	Moderate — case series, RCTs ongoing	Extensive, refractory NSV	Systemic risk profile; not yet standard
NB-UVB + JAK inhibitor	Dual: immune suppression + melanocyte stimulation	Emerging — meta-analysis 2025	Progressive NSV; refractory cases	Requires specialist coordination
Excimer laser	Targeted 308nm UVB — focal melanocyte stimulation	Moderate RCT evidence	Focal, localised lesions	Not practical for extensive disease
Surgical (grafting)	Autologous melanocyte transfer	Good for SV — moderate for NSV	Stable SV >12 months; limited areas	Disease must be stable; risk of Koebner
Vitamin D + E + Zinc supplementation	Antioxidant defence + immune modulation	Observational — consistent	Adjunct to all therapies	Not standalone — supportive role only
Alpha-lipoic acid / pseudocatalase	Antioxidant — catalase mimicry, H₂O₂ reduction	Small RCTs — promising	Adjunct in oxidative stress phenotype	Limited large-scale data

The Relapse Problem: Why Conventional Treatment Alone Is Insufficient

One of the most clinically frustrating aspects of vitiligo management is the high relapse rate after treatment cessation. The reason is mechanistically well understood: CD8+ tissue-resident memory T cells (Trm) persist in clinically repigmented skin. These Trm cells retain their autoimmune programme and reactivate melanocyte destruction when the immunosuppressive treatment is withdrawn — explaining why patients who respond beautifully to ruxolitinib or NB-UVB frequently relapse within weeks to months of stopping.³

This is not a failure of the treatment. It is a consequence of treating the downstream effector mechanism (the JAK-STAT inflammatory cascade) without addressing the upstream immunological memory (the Trm cells) or the predisposing terrain (oxidative burden, vitamin D insufficiency, gut immune dysregulation, autoimmune co-conditions). It is precisely why a functional medicine layer of investigation — running alongside conventional treatment — has clinical rationale: if the oxidative stress that triggers the cascade can be reduced, and if the immune regulatory environment can be improved through vitamin D optimisation, gut repair, and autoimmune terrain management, the threshold for Trm reactivation may be meaningfully raised even after treatment withdrawal.

What triggers vitiligo to spread?

The Koebner phenomenon, oxidative stress amplification, and immune cascade feedback are the primary drivers of vitiligo spread. Physical trauma (including sunburn, friction, procedures), chemical exposures, significant psychological stress, and intercurrent infections can all trigger new lesion formation or extension of existing lesions by activating the IFN-γ/JAK-STAT cascade in previously unaffected skin. Rapidly progressive disease — defined as new lesion formation or significant extension over a 6-month period — is the key indicator for more aggressive systemic intervention (oral JAK inhibitors, systemic steroids) rather than waiting for topical therapy response.^5,11

Can vitiligo go away on its own?

Spontaneous repigmentation occurs in a minority of vitiligo patients — estimated at 10–20% — and is most common in children, in recently-onset lesions, and in areas with intact hair follicle melanocyte reservoirs. It is not a reliable therapeutic strategy. The natural history of untreated non-segmental vitiligo is typically progressive — new lesions continue to form, and existing lesions expand over years to decades. Segmental vitiligo tends to stabilise after initial rapid progression, but does not repigment spontaneously to a meaningful degree. Early treatment improves long-term outcomes: halting active melanocyte destruction before follicular melanocyte reservoirs are depleted maximises the potential for repigmentation.^1,5

Frequently Asked Questions: Vitiligo

Is vitiligo autoimmune?

Yes — vitiligo is now firmly classified as an autoimmune condition driven by CD8+ cytotoxic T-cell–mediated destruction of melanocytes, orchestrated through the IFN-γ/CXCL9/CXCL10/CXCR3 signalling axis. This classification is what prompted the development of JAK inhibitors as targeted treatments and explains the strong association with other autoimmune conditions including Hashimoto's thyroiditis, Graves' disease, type 1 diabetes, alopecia areata, and rheumatoid arthritis.^2,3,5

What nutritional deficiencies are associated with vitiligo?

The 2024 meta-analysis (Iraji et al., 47 studies) confirmed significantly lower vitamin D, vitamin E, and zinc in vitiligo patients compared to controls. Vitamin D deficiency impairs regulatory T-cell function; vitamin E deficiency reduces the antioxidant protection of melanocyte membranes; zinc deficiency impairs catalase and superoxide dismutase activity — the enzymes that neutralise the hydrogen peroxide accumulation documented in vitiligo skin. Importantly, selenium should not be supplemented indiscriminately in vitiligo — elevated selenium levels are associated with increased vitiligo risk (OR 4.31).⁴

How effective is ruxolitinib cream for vitiligo?

Ruxolitinib cream 1.5% is the first FDA- and EMA-approved treatment specifically for non-segmental vitiligo, approved in 2022–2023. In Phase 3 trials, approximately 30% of patients achieved F-VASI75 (75% improvement in facial vitiligo scoring) at 24 weeks, compared to ~8% with vehicle cream. Facial lesions respond significantly better than acral or body lesions. Response continues to improve beyond 24 weeks. The major limitation is relapse after cessation — driven by persistent Trm cells that retain autoimmune memory in the skin.^3,11,12

Does stress cause vitiligo?

Psychological stress is among the most commonly reported triggers for vitiligo onset and flare in patient-reported data, and there is a plausible mechanism: stress-induced catecholamines generate ROS in melanocytes, and elevated cortisol reduces Treg cell activity — lowering the immunological threshold for autoreactive CD8+ T-cell activation. Stress management is therefore a clinically relevant adjunct to any vitiligo treatment protocol, though it is not a standalone intervention for active disease.^5,6

Is NB-UVB or ruxolitinib better for vitiligo?

They are complementary rather than competing. NB-UVB works by stimulating melanocyte migration from follicular reservoirs and has decades of safety data — it is the established first-line for extensive disease. Ruxolitinib cream suppresses the active autoimmune attack. The 2025 meta-analysis confirms that combining both produces faster and more complete repigmentation than either alone — making combination therapy the emerging standard of care for progressive or extensive non-segmental vitiligo, particularly facial involvement.^3,12

✦ Functional Skin Intervention — Vitiligo and Autoimmune Skin Conditions

A functional assessment for vitiligo goes beyond topical management — investigating nutritional deficiencies, oxidative stress markers, thyroid autoimmunity, gut permeability, and immune regulatory status. Understanding the internal terrain driving melanocyte destruction is the first step to a treatment plan that addresses both the surface and the source.

Concerned about vitiligo progression or treatment resistance?

Book a clinical consultation to assess the full picture — from conventional treatment options including NB-UVB and topical JAK inhibitors, to a functional investigation of the nutritional and immune drivers.

Book a consultation →

References

Zhang Y, Cai Y, Shi M, et al. The prevalence of vitiligo: a meta-analysis. PLoS One. 2016;11(9):e0163806. doi:10.1371/journal.pone.0163806.
Liu H, Wang Y, Le Q, Tong J, Wang H. The IFN-γ-CXCL9/CXCL10-CXCR3 axis in vitiligo: pathological mechanism and treatment. Eur J Immunol. 2024;54(4):e2250281. doi:10.1002/eji.202250281.
Systematic review: Efficacy of JAK inhibitor combined with phototherapy in non-segmental vitiligo. PMC. 2025. PMC12777791.
Iraji F, Seyedyousefi S, Heidari A. Serum vitamins and trace elements in vitiligo patients: a systematic review and meta-analysis of observational studies (47 studies). JEADV Clin Pract. 2024. doi:10.1002/jvc2.432.
Global Vitiligo Guidelines 2025 — Diagnosis and Management Summary. Medscape Reference / JEADV. 2025.
Zhang J, Hu W, Wang P, Ding Y, Wang H, Kang X. Research progress on targeted antioxidant therapy and vitiligo. Oxid Med Cell Longev. 2022:1821780. doi:10.1155/2022/1821780.
Białczyk A, Wełniak A, Kamińska B, Czajkowski R. Oxidative stress and potential antioxidant therapies in vitiligo: a narrative review. Mol Diagn Ther. 2023;27(6):723–739.
Diotallevi F, Gioacchini H, De Simoni E, et al. Vitiligo, from pathogenesis to therapeutic advances: state of the art. Int J Mol Sci. 2023;24(5):4910. doi:10.3390/ijms24054910.
Circulating vitamin D levels and risk of vitiligo: evidence from meta-analysis and two-sample Mendelian randomisation. Front Nutr. 2021;8:782270. PMC8727691.
Huo J, Liu T, Huan Y, Li F, Wang R. Serum level of antioxidant vitamins and minerals in patients with vitiligo, a systematic review and meta-analysis. J Trace Elem Med Biol. 2020;62:126570. doi:10.1016/j.jtemb.2020.126570.
Cunningham KN, Rosmarin D. Vitiligo treatments: review of current therapeutic modalities and JAK inhibitors. Am J Clin Dermatol. 2023;24(2):165–186. doi:10.1007/s40257-022-00752-6.
Harris JE, Rashighi M, Nguyen N, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata. J Am Acad Dermatol. 2016;74(2):370–371; and: Rothstein B, et al. Treatment of vitiligo with topical ruxolitinib. J Am Acad Dermatol. 2017;76:1054–1060.

Joey .